Chemicals are disclosed which are useful for inhibiting the actions of adenosine in mammals, comprising: L-propranolol, or D-propranolol, or alprenolol and derivatives thereof for parenteral or topical administration are disclosed for purposes of achieving desired circulating concentrations in the range of 10 nanogram to 10 milligrams per kilogram.D-Propranolol is of special interest because it is relatively inactive as a .beta.-adrenergic blocking agent. Specific uses of D-propranolol include the treatment of asthma, chronic obstructive pulmonary disease, A-V node conduction disturbances; apnea of preterm infants, pulmonary hypertension, headaches, migraine, and in attention-deficit disorder. D-Propranolol might also be used as a substitute for xanthines in beverages to produce a feeling of well being, awakeness, awareness and increased performance.

The United States of America as represented by the Secretary of the

D-propranolol as a selective adenosine antagonist

The present invention relates to Compound T62, pharmaceutically acceptable salts thereof, and their use in medicine as allosteric adenosine A.sub.1 receptor enhancers and uses including treatment of pain, for example, persistent chemical pain, neuropathic pain and acute pain states such as that induced by chemical irritation, gastrointestinal disturbance, migraine and all forms of headache. Compound T62 is represented by the formula: ##STR1##

adenosine/cefaleia

D-propranolol as a selective adenosine antagonist

Method for treating pain in humans

O mais completo banco de dados de ervas medicinais apoiado pela ciência